COVID-19 in patients with lung cancer von Luo, J., Rizvi, H., Preeshagul, I.R., Egger, J.V., Hoyos, D., Bandlamudi, C., McCarthy, C.G., Falcon, C.J., Schoenfeld, A.J., Arbour, K.C., Chaft, J.E., Daly, R.M., Drilon, A., Eng, J., Iqbal, A., Lai, W.V., Li, B.T., Lito, P., Namakydoust, A., Ng, K., Offin, M., Paik, P.K., Riely, G.J., Rudin, C.M., Yu, H.A., Zauderer, M.G., Donoghue, M.T.A., Łuksza, M., Greenbaum, B.D., Kris, M.G., Hellmann, M.D.

Volltext

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers von Sabari, J.K., Leonardi, G.C., Shu, C.A., Umeton, R., Montecalvo, J., Ni, A., Chen, R., Dienstag, J., Mrad, C., Bergagnini, I., Lai, W.V., Offin, M., Arbour, K.C., Plodkowski, A.J., Halpenny, D.F., Paik, P.K., Li, B.T., Riely, G.J., Kris, M.G., Rudin, C.M., Sholl, L.M., Nishino, M., Hellmann, M.D., Rekhtman, N., Awad, M.M., Drilon, A.

Volltext

Characterization of on-target adverse events caused by TRK inhibitor therapy von Liu, D., Flory, J., Lin, A., Offin, M., Falcon, C.J., Murciano-Goroff, Y.R., Rosen, E., Guo, R., Basu, E., Li, B.T., Harding, J.J., Iyer, G., Jhaveri, K., Gounder, M.M., Shukla, N.N., Roberts, S.S., Glade-Bender, J., Kaplanis, L., Schram, A., Hyman, D.M., Drilon, A.

Volltext

Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors von Shaverdian, N., Beattie, J., Thor, M., Offin, M., Shepherd, A.F., Gelblum, D.Y., Wu, A.J., Simone, C.B., Hellmann, M.D., Chaft, J.E., Rimner, A., Gomez, D.R.

Volltext

Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers von Wu, J., Liu, D., Offin, M., Lezcano, C., Torrisi, J. M., Brownstein, S., Hyman, D. M., Gounder, M. M., Abida, W., Drilon, A., Harding, J. J., Sullivan, R. J., Janku, F., Welsch, D., Varterasian, M., Groover, A., Li, B. T., Lacouture, M. E.

Volltext

425 Case-based Simulation: Critical Conversations Around Resuscitation of the Critically Ill or Injured Patient von Lamba, S, Nagurka, R, Offin, M, Compton, S

Volltext

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK , ROS1 , and ALK fusion-positive solid tumors von Liu, Dazhi, Offin, Michael, Harnicar, Stephen, Li, Bob T, Drilon, Alexander

Volltext

Multi-Center Phase I Study of Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases (BM) or Leptomeningeal Metastases (LM) Harboring PI3K Pathway... von Imber, B.S., Kotecha, R., Blau, M.H., Friend, J., Young, R.J., Offin, M., Michelle, R., Diamond, E., Yang, J.T.

Volltext

Abstract No. 13 Safety and Efficacy of Percutaneous Cryoablation for Primary and Metastatic Intrathoracic, Pleural Based Tumors von Alexander, E., Petre, N., Offin, M., Zauderer, M., Zhao, K., Sotirchos, V., Ziv, E., Solomon, S.

Volltext

EP12.02-08 Frequency and Outcomes of Leptomeningeal Metastases in Patients with Fusion-Positive Lung Cancers von Chen, M., Sui, J., Wilcox, J., Yang, S.R., Imber, B., Offin, M., Yu, H., Kris, M.G., Drilon, A.E.

Volltext

P2.10-06 Brain Metastases in Patients with Fusion-Positive Lung Cancers von Sui, J.S., Chen, M.F., Wilcox, J., Yang, S.R., Li, B.T., Riely, G.J., Offin, M., Yu, H.A., Kris, M.G., Drilon, A.E.

Volltext

Exploratory Analysis of ctDNA and Imaging Response in the Phase I/II CHORUS Study of Canakinumab with Chemoradiation and Durvalumab Consolidation for Stage III NSCLC von Shaverdian, N., Offin, M., Charalambous, K., Gelblum, D., Santini, F., Boe, L.A., Shepherd, A.F., Gewanter, R.M., Shin, J.Y., Rimner, A., Kris, M.G., Preeshagul, I., Paik, P., Eng, J., Iqbal, A., Ng, K., Shah, R., Berger, M., Gomez, D.R., Chaft, J.

Volltext

P2.09-14 Clinical Characteristics and Outcomes of Patients with EGFR-mutant Lung Cancer with Acquired BRAF Alterations von Sui, J., Yang, S.R., Bowman, A.S., Vankayala, P., Falcon, C., Somwar, R., Drilon, A.E., Riely, G.J., Kris, M.G., Ladanyi, M., Yu, H.A., Offin, M.

Volltext

MA06.13 Updated Safety Analysis of Encorafenib Plus Binimetinib in Patients with BRAF V600e-Mutant Metastatic NSCLC from PHAROS Study von Smit, E., Ahn, M.-J., Dagogo-Jack, I., Felip, E., Gelsomino, F., Johnson, B., Johnson, M., Negrao, M.V., Offin, M., Ramalingam, S., Sanborn, R., Tsao, A., Wilner, K., Alcasid, A., Usari, T., Zhang, X., Riely, G.

Volltext

46MO Promoting functional persistence in solid tumor CAR T-cell therapy: Mesothelin-targeted CAR (M28z1XXPD1DNR) with T-cell intrinsic PD1 dominant negative receptor von Adusumilli, P.S., Amador, A.M., Chintala, N., Hou, Z., Offin, M., Pineda, J., Senechal, B., Quach, H.T., Bellis, R., Banerjee, S., Saini, J., Zhu, A., Daly, R.M., Sadelain, M., Rivière, I., Zauderer, M., O'Cearbhaill, R.

Volltext

Predicting Tumor Progression in Early Stage Non-small Cell Lung Cancer Using Pre-treatment Imaging von Thor, M., Fitzgerald, K.J., Iyer, A., Apte, A., Oh, J.H., Chaft, J., Wu, A.J., Offin, M., Gelblum, D., Deasy, J.O., Rimner, A.

Volltext

Real-World Evaluation of Consolidative Durvalumab in Locally Advanced Non-Small-Cell Lung Cancer Treated with Definitive Chemoradiation von Shaverdian, N., Zhang, Z., Lobaugh, S., Deasy, J.O., Offin, M., Preeshagul, I., Hellmann, M.D., Chaft, J., Shepherd, A.F., Gelblum, D., Lee, N., Gomez, D., Wu, A.J., Rimner, A.

Volltext

MA16.03 CRISPR Screen Reveals XPO1 as a Therapeutic Target Strongly Sensitizing to First and Second Line Therapy in Small Cell Lung Cancer von Quintanal-Villalonga, A., Taniguchi, H., Hao, Y., Chow, A., Zhan, Y., Chavan, S., Uddin, F., Allaj, V., Manoj, P., Shah, N., Chan, J., Offin, M., Egger, J., Bhanot, U., Qiu, J., De Stanchina, E., Sen, T., Poirier, J.t., Rudin, C.

Volltext

2MO XPO1 inhibition strongly sensitizes to first-line and second-line therapy in small cell lung cancer von Quintanal-Villalonga, Á., Taniguchi, H., Hao, Y., Chow, A., Zhan, Y.A., Uddin, F., Allaj, V., Manoj, P., Shah, N., Chan, J.M., Offin, M., Ciampricotti, M., Egger, J., Qiu, J., De Stanchina, E., Hollmann, T.J., Koche, R.P., Sen, T., Poirier, J.T., Rudin, C.M.

Volltext

MA06.08 A Safety Study of Avelumab plus SBRT in Malignant Mesothelioma von Rimner, A., Yorke, E., Gelblum, D., Shepherd, A., Guttmann, D., Iqbal, A., Daly, R., Offin, M., Fiore, J., Namakydoust, A., Li, H., Mccune, M., Gelb, E., Taunk, N., Von Reibnitz, D., Adusumilli, P., Center, M.S.K., Zauderer, M.

Volltext